West Family Investments Inc. Purchases New Position in Edwards Lifesciences Corporation $EW

West Family Investments Inc. bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,655 shares of the medical research company’s stock, valued at approximately $208,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Econ Financial Services Corp acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $889,000. Randolph Co Inc bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $301,000. Pacific Capital Partners Ltd acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $1,760,000. Arkadios Wealth Advisors acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $300,000. Finally, Mirova US LLC increased its stake in shares of Edwards Lifesciences by 56.2% in the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on EW shares. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Barclays reaffirmed an “overweight” rating and set a $99.00 price target (up from $95.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. UBS Group reissued a “neutral” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Finally, Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Stock Performance

Shares of EW opened at $86.74 on Monday. The stock has a 50 day moving average of $79.93 and a 200 day moving average of $78.48. The company has a market capitalization of $50.34 billion, a price-to-earnings ratio of 12.48, a PEG ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.40. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.